GLP-1 drugs (unspecified)
What studies of GLP-1 drugs (unspecified) found
At a glance, by condition
Preventing long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty), for overall symptoms.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with GLP-1 drugs (unspecified) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- GLP-1 drugs (unspecified) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Daily life and health overall
Overall symptoms1 study · 5,130 people took GLP-1 drugs (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised14,215 with outcome data · 12 months
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of GLP-1 drugs (unspecified) on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus. (2026) preprint
- People in the study
- 14,215 with outcome data
- Dose
- —
- Outcome
- Long COVID via Long COVID diagnosis
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: average healthcare utilization rate, sex, age, race, data provider, BMI, tobacco use, medical conditions, medication use, and biomarker measurements
We adjusted for the following data in our model: average healthcare utilization rate, sex, age, race, data provider, BMI, tobacco use, medical conditions
- Selection of participants
- Moderate. comparison group: SGLT2i chosen as active comparator.
SGLT2is are a clinically relevant active comparator frequently used in prior evaluations of GLP therapies.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Censoring for no healthcare interactions during the 12-month follow-up; per-arm not analysed not reported.
We considered an individual lost to follow-up by censoring (informative right censoring) if/when they had no healthcare interactions during the 12-month follow-up period.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.2026 · compared with another group · 14,215 with outcome data · preprint
Summary
This retrospective cohort study used electronic health record data from the National Clinical Cohort Collaborative (N3C). It included 14,215 individuals with type 2 diabetes and COVID-19 diagnosed between October 1, 2021, and April 1, 2023. Of these, 5,130 were prescribed GLP medications and 9,085 were prescribed SGLT2i medications. The study compared the 12-month cumulative incidence of mortality and Long COVID (Long COVID diagnosis and probable Long COVID) between the groups. At 12 months, GLP prescription, compared with SGLT2i prescription, was associated with a lower risk of mortality (adjusted risk ratio 0.71, 95% CI 0.53 to 0.95; unadjusted risk ratio 0.44, 95% CI 0.35 to 0.55). The study did not detect a significant relationship for Long COVID diagnosis (adjusted risk ratio 1.01, 95% CI 0.80 to 1.27) or probable Long COVID (adjusted risk ratio 0.94, 95% CI 0.88 to 1.01). Side effects and withdrawals due to harms were not reported. The authors state that the limited clinical uptake of the Long COVID diagnosis code is a limitation, with the sample showing approximately 2% 12-month cumulative incidence. They also state potential exposure misclassification, limited generalizability of N3C, and possible residual confounding as limitations.